ABSTRACT
The drug most extensively investigated in association with IFN- is cytosine arabinoside (Ara-C, cytarabine), based on experimental and clinical observations. Recently, an oral formulation of Ara-C (cytarabine octaphosphate, YNK01) has been proposed to improve overall compliance with the drug association.
